⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ATNM News
Actinium Pharmaceuticals, Inc
Targeted Alpha Therapy Market Size to Hit USD 11.52 Billion by 2035 from USD 1.25 Billion in 2025 at CAGR of 24.9% - SNS Insider
globenewswire.com
ATNM
Actinium Pharmaceuticals, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment Conference
prnewswire.com
ATNM
Actinium Pharmaceuticals Announces Actimab-A Intellectual Property and Manufacturing Advances and Provides NYSE American Listing Update
prnewswire.com
ATNM
Form 8-K
sec.gov
ATNM
Form 8-K
sec.gov
ATNM
Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer
prnewswire.com
ATNM
Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Prostate Cancer Models
prnewswire.com
ATNM
Actinium Appoints Accomplished Oncology Expert Steffen Heeger MD, MSc as Chief Medical Officer to Drive Rejuvenated Pipeline Development
prnewswire.com
CNTA
ATNM
Actinium Pharmaceuticals Presents New Radiochemistry Data at SNMMI 2026 Demonstrating That CAR Optimization Improves Tumor Targeting and Pharmacokinetics of Actinium-225 Radioconjugates
prnewswire.com
ATNM
Actinium Pharmaceuticals Receives Two Patent Allowances Spanning Its Actimab-A and Iomab-ACT Programs
prnewswire.com
ATNM